Ten Years On, Access To Biosimilars Still Patchy in EU
This article was originally published in SRA
Executive Summary
April saw the 10th anniversary of the first biosimilar approval in Europe - Sandoz' Omnitrope (somatropin) - which was launched in 2006. But a decade on, even with 20 biosimilar products now available and many more to come as big biological drugs lose their patent protection, there are still significant barriers to biosimilar penetration and wide variations in patient access across the EU that need to be addressed.
You may also be interested in...
Biosimilar Confidence And Knowledge Needed In Europe, Say Experts
European biosimilar market penetration varies widely across the EU member states and disease groups, with different government policies on promotion, purchasing and communication leading to mistrust. The European Commission is looking to boost confidence in biosimilars to support their uptake on a much wider scale across Europe, and to get a bird's eye view of what is driving or hindering the EU market for biosimilars.
Biosimilar Confidence And Knowledge Needed In Europe, Say Experts
European biosimilar market penetration varies widely across the EU member states and disease groups, with different government policies on promotion, purchasing and communication leading to mistrust. The European Commission is looking to boost confidence in biosimilars to support their uptake on a much wider scale across Europe, and to get a bird's eye view of what is driving or hindering the EU market for biosimilars.
New Zealand Hikes Fees To Reflect Changes In Drug Applications
Following a consultation last year, Medsafe has set new fee levels that take account of both cost-recovery principles and a 4.2% increase in the consumer price index.